The firm reported $52.8 million in revenues, up from $26.3 million during the same period last year and beat the average Wall Street revenue estimate of $44.9 million.
The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.
The company is eyeing a launch for its IVD kits at the beginning of next year, as evidence grows for the integration of TMB analysis into the clinical care of cancer patients.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
The companies plan to develop a broad NGS panel to analyze all known biomarkers for cancer drugs, including tumor mutation burden and microsatellite instability.
The companies will develop a version of Illumina's TruSight 170 sequencing panel for two of Loxo's targeted oncology drugs.
A private payor survey by ClearView Healthcare Partners found that medical directors viewed CMS's decision with caution; half had no plans to align commercial plan coverage.
The ctDNA assay will be used to select patients for Phase 3 of Five Prime's registrational trial investigating bemarituzumab in gastric cancer patients.
The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.
The test is approved as a companion diagnostic that can determine which advanced breast cancer patients have BRCA1/2 genetic mutations and will likely respond to Lynparza.
China has been a key focus for Agena, which established a Shanghai subsidiary in 2015.
The company plans to grow its business based on the FDA approval and preliminary national coverage determination for its FoundationOne CDx test last year.
For full-year 2017, the company reported $152.9 million in revenues, up 31 percent over 2016.
The company plans to submit its 650- to 700-gene panel, which will include microsatellite instability testing, to the FDA for approval as a companion diagnostic.
A perspective that hasn't gotten as much attention is that the CMS draft coverage decision could be bad for patients by increasing off-label drug use based on the results of NGS panels.
Excluding the sale of the company's colorectal cancer patents to Exact Sciences, its 2017 revenues rose 13 percent.
The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.
BMS amended an ongoing Phase III study of Opdivo and Yervoy to evaluate outcomes based on tumor mutational burden using Foundation Medicine's NGS companion diagnostic.
The biomarker has been associated with retinal ganglion cell death and is upregulated in mouse models of chronic glaucoma.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.
The Los Angeles Times reports that only a third of California students meet the state's new science standards.
In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.